Advanced in Gastroesophageal Junction Cancer

Dr. Patrick Ott

Hematology | Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Gastroesophageal Junction Cancer
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Patrick Ott is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Ott is rated as an Advanced provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Melanoma, Gastroesophageal Junction Cancer, Small Cell Lung Cancer (SCLC), Metastatic Uveal Melanoma, and Tissue Biopsy.

His clinical research consists of co-authoring 173 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Gastroesophageal Junction Cancer.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Ott has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma
A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma
Enrollment Status: Recruiting
Publish Date: March 05, 2025
Intervention Type: Drug, Biological
Study Drugs: CDX-301, NEOVAX, Nivolumab
Study Phase: Phase 1
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Biological, Drug
Study Drugs: Ipilimumab, Nivolumab, Prednisone, Tacrolimus
Study Phase: Phase 1
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: NeoVax, Ipilimumab
Study Phase: Phase 1
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma
A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced Melanoma
A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Nivolumab, NeoVax plus Montanide, Ipilimumab
Study Phase: Phase 1
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drugs: Vancomycin Pretreatment, Nivolumab, SER-401
Study Phase: Phase 1
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: Tremelimumab, MEDI3617
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma
A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma
Enrollment Status: Terminated
Publish Date: March 10, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Dabrafenib, Ipilimumab, Nivolumab, Trametinib
Study Phase: Phase 1
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 31, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Enrollment Status: Completed
Publish Date: February 25, 2021
Intervention Type: Biological, Other
Study Phase: Phase 1
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Enrollment Status: Terminated
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

173 Total Publications

Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response.
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response.
Journal: Pigment cell & melanoma research
Published: April 20, 2025
Similar Doctors
Howard P. Safran
Elite in Gastroesophageal Junction Cancer
Dr. Howard P. Safran
Hematology Oncology | Hematology | Oncology
Elite in Gastroesophageal Junction Cancer
Dr. Howard P. Safran
Hematology Oncology | Hematology | Oncology

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (39.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Howard Safran is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Safran is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, Stomach Cancer, and Pancreaticoduodenectomy.

Distinguished in Gastroesophageal Junction Cancer
Dr. Jeffrey W. Clark
Oncology | Hematology
Distinguished in Gastroesophageal Junction Cancer
Dr. Jeffrey W. Clark
Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Clark is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Clark is rated as an Elite provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Clark is currently accepting new patients.

Distinguished in Gastroesophageal Junction Cancer
Dr. James M. Cleary
Oncology | Hematology Oncology
Distinguished in Gastroesophageal Junction Cancer
Dr. James M. Cleary
Oncology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Cleary is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Cleary is rated as a Distinguished provider by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Hepato-Pancreato-Biliary Surgery, and Tissue Biopsy. Dr. Cleary is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ott's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile